S. Pignata reviews the results of studies performed in women with gynecological malignancies and presented at ASCO 2015. He provides an expert insights on benefit of trebaninib in patients with ascites in a subgroup analysis of TRINOVA-1 study, biomarker driven PENELOPE study of pertuzumab and chemotherapy in platinum-resistant ovarian cancer, toxicity data from adding adjuvant chemotherapy to radiotherapy in the PORTEC-3 study, and risk for uterine cancer following salpingo-oophorectomy in women with BRCA mutations.